FOXO1

Overview

FOXO1 (forkhead box protein O1) is a transcription factor in the forkhead box O family that regulates gene expression programs involved in metabolism, stress resistance, cell survival, differentiation, and immune function. As a nuclear transcriptional regulator, FOXO1 integrates upstream signaling cues from pathways such as PI3K/AKT and sirtuin 1, and its activity is strongly influenced by subcellular localization, including nuclear translocation.

In biomedical research, FOXO1 is widely studied as a context-dependent regulator in cancer, metabolic disease, cardiovascular injury, neurodegeneration, and aging. Depending on cell type and disease setting, FOXO1 can support tumor suppression, T cell stem-like differentiation, energy metabolism, autophagy, and geroprotective programs, while dysregulated FOXO1 signaling has also been linked to inflammatory and degenerative phenotypes.

Recent Publications Focus

Below is a summary of the newest research publications targeting FOXO1 (sorted by publication date).

Recent investigations have established FOXO1 as a versatile therapeutic target across diverse pathological conditions. The forkhead box O transcription factor FOXO1 has emerged as a central regulator implicated in autoimmune diseases, neurodegenerative disorders, metabolic dysfunction, and cardiac pathology. These studies collectively demonstrate that both inhibition and modulation of FOXO1 activity can yield therapeutic benefit depending on the disease context and mechanism.

FOXO1 inhibition has shown therapeutic promise in several inflammatory and metabolic diseases. A novel vakognavine-type diterpenoid alkaloid, delphyuanine A, directly targets FOXO1 to suppress its nuclear translocation in rheumatoid arthritis, thereby inhibiting macrophage inflammation, promoting M2 polarization, and suppressing nuclear factor kappa B signaling [42357943]. Yangxinshi Tablet ameliorates post-myocardial infarction heart failure by inhibiting the FOXO1/PDK4 signaling axis, restoring cardiac energy metabolism and adenosine triphosphate production through enhanced tricarboxylic acid cycle activity [42062031]. In Alzheimer's disease, ghrelin protects astrocytes from amyloid-beta-induced mitochondrial dysfunction through UCP2-mediated inhibition of FOXO1 nuclear translocation, subsequently restoring glycolytic function and neurotrophic support [42185568]. At the microRNA level, suppression of miR-144 in microglia ameliorates type 2 diabetes-associated cognitive impairment by upregulating FOXO1 and AdipoR signaling, thereby reducing neuroinflammation and Tau phosphorylation [42086968]. Compound screening has identified multiple agents, including 1,25-dihydroxyvitamin D3, all-trans-retinoic acid, and magnolol, that inhibit FOXO1/3a transcriptional activity to suppress dexamethasone-induced muscle atrophy [41790122].

Conversely, FOXO1 enhancement demonstrates therapeutic value in specific disease contexts. Gene therapy-mediated FOXO1 overexpression in corneal endothelial cells preserves mitochondria-associated endoplasmic reticulum membrane integrity and calcium homeostasis, improving corneal function in models of type 1 diabetes mellitus and Fuchs endothelial corneal dystrophy [42070230]. Additionally, ponatinib enhances FOXO1 transcriptional function and TCF7 activity through off-target inhibition of LCK and PI3K signaling, promoting CD8+ T stem cell memory differentiation and improving antitumor immune responses, including enhanced chimeric antigen receptor T cell efficacy [41946709].

These findings collectively underscore FOXO1's pleiotropic role as a metabolic and immunological regulator. Therapeutic strategies are increasingly tailored to disease pathogenesis: FOXO1 inhibition for autoimmune and metabolic diseases where its activity exacerbates pathology, and FOXO1 enhancement for degenerative and immunological conditions where its transcriptional functions promote cellular restoration and immune competence.